Equities research analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report earnings per share of ($0.10) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from ($0.21) to ($0.04). Collegium Pharmaceutical posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 81.5%. The business is scheduled to announce its next quarterly earnings report on Wednesday, March 6th.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.85) per share for the current financial year, with EPS estimates ranging from ($0.96) to ($0.79). For the next year, analysts forecast that the business will post earnings of $0.54 per share, with EPS estimates ranging from $0.12 to $0.87. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The firm had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The firm’s revenue for the quarter was up 485.0% compared to the same quarter last year. During the same period last year, the company earned ($0.45) EPS.
Several analysts have issued reports on COLL shares. Cantor Fitzgerald dropped their target price on Collegium Pharmaceutical from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, August 9th. BidaskClub cut Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. Finally, ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 13th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $31.71.
NASDAQ COLL traded down $0.27 during midday trading on Friday, hitting $19.41. 16,592 shares of the company traded hands, compared to its average volume of 482,212. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. The stock has a market capitalization of $641.68 million, a PE ratio of -7.92 and a beta of 0.29. Collegium Pharmaceutical has a 52 week low of $13.70 and a 52 week high of $29.90.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the sale, the director now owns 361,000 shares of the company’s stock, valued at approximately $5,967,330. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth $213,000. Atria Investments LLC raised its stake in Collegium Pharmaceutical by 81.3% in the 3rd quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock worth $226,000 after acquiring an additional 6,866 shares during the last quarter. Jefferies Group LLC purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $271,000. Capital Fund Management S.A. purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $286,000. Finally, Man Group plc purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth $287,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Read More: Hedge Funds – Risk or Reward?
Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.